Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet

1. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial  The Lancet
2. Mavacamten Shines in Phase 3 Trial; Could Be First Specific Treatment for Obstructive HCM  AJMC.com Managed Markets Network
3. ESC TV at ESC Congress 2020 - EXPLORER-HCM (Discussant)  European Society of Cardiology
4. ESC: MyoKardia's mavacamten boosts heart function in phase 3, teeing up 2021 filing  FierceBiotech
5. Novel Tx Turns in Favorable Performance in Obstructive HCM  MedPage Today
6. View Full Coverage on Google News

(CLICK HERE TO READ AND SEE MORE)